{{Rsnum
|rsid=2375699
|Gene=DNAJC6
|Chromosome=1
|position=65342598
|Orientation=minus
|GMAF=0.4578
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DNAJC6
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 25.7 | 42.5 | 31.9
| HCB | 44.5 | 43.8 | 11.7
| JPT | 38.1 | 46.9 | 15.0
| YRI | 23.3 | 45.2 | 31.5
| ASW | 24.6 | 61.4 | 14.0
| CHB | 44.5 | 43.8 | 11.7
| CHD | 47.2 | 40.7 | 12.0
| GIH | 35.6 | 48.5 | 15.8
| LWK | 28.2 | 47.3 | 24.5
| MEX | 34.5 | 51.7 | 13.8
| MKK | 25.2 | 54.8 | 20.0
| TSI | 15.7 | 55.9 | 28.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2375699
|Name_s=
|Gene_s=DNAJC6
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00000006. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109370
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2375699
|overall_frequency_n=68
|overall_frequency_d=128
|overall_frequency=0.53125
|n_genomes=44
|n_genomes_annotated=0
|n_haplomes=65
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}